NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00411229,Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer,https://clinicaltrials.gov/study/NCT00411229,CLASSIC,COMPLETED,"Primary:

* To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to observation alone in terms of 3 year disease-free survival (DFS) rate in chemotherapy-na√Øve patients who underwent potentially curative resection for gastric cancer.

Secondary:

* To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin adjuvant therapy.",NO,Stomach Neoplasms,DRUG: Capecitabine|DRUG: Oxaliplatin,"Recurrence of the original cancer, From the beginning to end of the study|Development of a new gastric cancer, From beginning to end of study|Death due to any cause, From the beginning to the end of study|Adverse events, From beginning to end of study|Clinical laboratory tests, From beginning to end of study",,,Sanofi,Hoffmann-La Roche,ALL,"ADULT, OLDER_ADULT",PHASE3,1035,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,L_9570|M017527,2006-06,2012-11,2012-11,2006-12-13,,2013-02-20,"Sanofi-Aventis, Beijing, China|Sanofi-Aventis, Seoul, Korea, Republic of|Sanofi-Aventis, Taipei, Taiwan",
